• ABL Diagnostics entered a strategic partnership with ABIONYX Pharma focused on viral safety and viral clearance work for CER-001.
• TEXCELL will run viral safety and clearance studies tied to validation batches for CER-001 manufacturing, supporting ABIONYX’s regulatory program.
• Deal strengthens TEXCELL’s positioning in biopharma development services across major markets, including Europe, the US, Asia.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ABL Diagnostics SA published the original content used to generate this news brief via Business Wire (Ref. ID: 202609101200BIZWIRE_USPR_____20260910_BW575436) on September 10, 2026, and is solely responsible for the information contained therein.